




Dr. Agarwal's Eye Hospital Limited
 Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
 Phone No. 91-44-39918669, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CIN : L85110TN1994PLC027366
 Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2017

S.No.	Particulars	Quarter Ended			Year to date figures for the Period Ended	
		31-Dec-17	30-Sep-17	31-Dec-16	31-Dec-17	31-Dec-16
1	Income					
	(a) Revenue from Operations	3,460.78	3,930.07	3,415.29	11,574.17	11,183.91
	(b) Other Income	96.36	47.33	9.97	163.55	65.56
	Total Income	3,556.14	3,977.40	3,425.26	11,737.72	11,252.47
2	Expenses					
	(a) Purchase of Stock-in-Trade	319.81	346.56	500.27	1,373.04	1,495.09
	(b) Changes in Inventories of Stock-in-Trade	98.81	93.64	(23.37)	(61.98)	83.15
	(c) Consumables	392.61	329.28	356.11	1,143.90	1,368.83
	(d) Consultancy Charges	518.00	475.98	506.20	1,490.62	1,518.98
	(e) Employee Benefit Expenses	885.22	809.19	829.51	2,496.77	2,427.78
	(f) Finance Costs	57.59	52.70	163.64	257.76	257.76
	(g) Depreciation and Amortisation Expense	268.54	255.41	208.14	738.95	601.72
	(h) Rent	437.88	413.94	409.26	1,274.95	1,218.60
	(i) Other Expenses	780.86	573.90	572.70	1,995.41	1,586.24
	Total Expenses	3,760.43	3,350.50	3,441.52	10,575.20	10,662.15
3	Profit / (Loss) before Exceptional Items and Tax (1-2)	(204.29)	626.90	(16.26)	1,162.52	590.32
4	Exceptional Items	-	-	-	-	-
5	Profit / (Loss) before Tax (3-4)	(204.29)	626.90	(16.26)	1,162.52	590.32
6	Tax Expense					
	- Current Tax	(26.50)	229.00	15.90	497.80	251.54
	- Deferred Tax	(44.98)	(12.10)	(20.17)	(96.19)	(54.50)
7	Net Profit / (Loss) for the period (5-6)	(132.81)	410.00	(11.99)	760.91	393.28
8	Other Comprehensive Income					
	(a) Items that will not be reclassified to the Statement of Profit and Loss					
	- Actuarial (loss) / gain on defined benefit obligation	(8.26)	(8.26)	0.04	(24.87)	0.12
	- Deferred Tax on Adjustments	2.86	2.86	(0.01)	8.61	(0.04)
	(b) Items that will be reclassified to the Statement of Profit and Loss					
	Total Other Comprehensive Income / (Loss) (net of tax)	(5.40)	(5.40)	0.03	(16.26)	0.08
9	Total Comprehensive Income / (Loss) (7+8)	(138.21)	404.60	(11.96)	744.65	393.36
10	Paid-up equity share capital / Face value Rs. 10/- each	470.00	470.00	470.00	470.00	470.00
11	Earnings Per Equity Share (EPS) (of Rs. 10/- each)					
	(a) Basic	(2.53)	8.72	(0.26)	16.19	8.37
	(b) Diluted	(2.53)	8.72	(0.26)	16.19	8.37
		(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)



M/A





Dr. Agarwal's Eye Hospital Limited
Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-39916699, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CIN : L85110TN1994PLC027366
Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2017

Notes:

1 The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their Meeting held on 2 February 2018. The above results for the quarter and nine months ended 31 December 2017 has also been subject to limited review by the Statutory Auditors of the Company.

2 The Company adopted Indian Accounting Standard ("Ind AS") from 1 April 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34: Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. The reconciliation between financial results for the quarter and nine months ended 31 December 2016, as previously reported (referred to as 'Previous GAAP') and Ind AS is as under:

Particulars	Amount in Rs. Lacs	
	Quarter Ended 31 December 2016	Period Ended 31 December 2016
Net profit / (loss) under Previous GAAP	(28.32)	344.95
Actuarial Gain on employee defined benefit funds recognised in Other Comprehensive Income	(0.04)	(0.12)
Interest income on Security Deposits	7.64	37.40
Amortisation of Lease Rentals	(7.46)	(36.96)
Amortisation of Finance Costs	(1.60)	(4.96)
Expected Credit Loss Adjustment	26.44	78.55
Impact of Deferred Tax in respect of the above Adjustments	(8.65)	(25.59)
Net profit / (loss) for the period under Ind AS	(11.99)	393.28
Other Comprehensive Income (net of tax)	0.03	0.08
Total Comprehensive Income / (Loss) under Ind AS	(11.96)	393.36

3 The Company operates in a single segment i.e. "Eye Care related Sales and Services" and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.


4 The Company has availed the exemption provided in the SEBI Circular dated 5 July 2016 with regard to the disclosure of the financial results for the year ended 31 March 2017.

By order of the Board


Place : Chennai

Date : 2 February 2018

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435664



MVA



INDEPENDENT AUDITOR'S REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the Quarter and Nine Months ended 31 December 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



V Balaji
Partner
(Membership No. 203685)

CHENNAI, 2 February 2018
VB/JT/RB/2018/02

